WO2011099031A1 - Antioxydants actifs pour tous les groupes d'âge - Google Patents

Antioxydants actifs pour tous les groupes d'âge Download PDF

Info

Publication number
WO2011099031A1
WO2011099031A1 PCT/IN2010/000872 IN2010000872W WO2011099031A1 WO 2011099031 A1 WO2011099031 A1 WO 2011099031A1 IN 2010000872 W IN2010000872 W IN 2010000872W WO 2011099031 A1 WO2011099031 A1 WO 2011099031A1
Authority
WO
WIPO (PCT)
Prior art keywords
folic acid
dha
recited
epa
folate
Prior art date
Application number
PCT/IN2010/000872
Other languages
English (en)
Inventor
Kamlesh Rajnikant Zota
Sanjay Agrawal
Ketan Chandulal Zota
Manukant Chandulal Zota
Himanshu Muktilal Zota
Original Assignee
Zota Health Care Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zota Health Care Limited filed Critical Zota Health Care Limited
Publication of WO2011099031A1 publication Critical patent/WO2011099031A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Definitions

  • FIELD OF INVENTION This invention is based on active antioxidants which are useful for all age group like adult, kids thereof.
  • a method of providing controlled release of a biologically active substance within a subject's digestive system comprising administering a biologically active substance to a subject's digestive system.
  • the biologically active substance is administered concurrently with one or more soluble fibers in an oral dosage unit.
  • the soluble fibers interact with the biologically active substance within the subject's digestive system to moderate and control the release of the biologically active substances in the subject's bloodstream. This provides more constant blood concentrations of the biologically active substances.
  • the amount of soluble fibers in the oral dosage unit is greater than 40% by weight, and in some cases greater than 50% by weight of the oral dosage unit.
  • the oral dosage unit typically contains from about 1 to 15g of soluble fiber, and in some cases from about 3 to 5g of soluble fiber.
  • the biologically active substance may contain phytonutrients that promote the subject's cardiovascular system, immune system, or weight management.
  • the main object of the invention is to provide an active antioxidant for the all age group.
  • Prior antioxidants targeted on the particular age group. This is one of the strong antioxidant as comparative to others. Deficiency of antioxidants or low level of the same can cause oxidative stress and hence eventually kill cells. For all this reasons antioxidants are so important for the body metabolism and it also helps in lowering down the cell aging.
  • STATEMENT OF INVENTION This invention is based on active antioxidants which are useful for all age group like adult, kids thereof. These are active antioxidants. They work on whole body as well as its metabolism.
  • This invention is based on the strong antioxidants which are essential for all age group.
  • Oxidation is a chemical reaction that transfers electrons from a substance to an oxidizing agent. Oxidation reactions can produce free radicals, which start chain reactions that damage cells. Antioxidants terminate these chain reactions by removing free radical intermediates, and inhibit other oxidation reactions by being oxidized themselves. As a result, antioxidants are often reducing agents such as thiols, ascorbic acid or polyphenols. Antioxidants are also widely used as ingredients in dietary supplements in the hope of maintaining health and preventing diseases such as cancer and coronary heart disease. Although initial studies suggested that antioxidant supplements might promote health, later large clinical trials did not detect any benefit and suggested instead that excess supplementation may be harmful.
  • antioxidants In addition to the uses of natural antioxidants in medicine, oxidation reactions are crucial for life, they can also be damaging; hence, plants and animals maintain complex systems of multiple types of antioxidants, such as glutathione, vitamin C, and vitamin E as well as enzymes such as catalase, superoxide dismutase and various peroxidases.
  • EPA Eicosapentaenoic acid (EPA or also icosapentaenoic acid) is an omega-3 fatty acid. EPA and its metabolites act in the body largely by their interactions with the metabolites of arachidonic acid; It is obtained in the human diet by eating oily fish or fish oil— cod liver, herring, mackerel, salmon, menhaden and sardine. It is also found in human milk. It's beneficial potential in mental conditions, such as schizophrenia.. EPA may affect depression, and importantly, suicidal behavior. EPA has inhibitory effect on CYP2C9 and CYP2C19 hepatic enzymes.
  • DHA Docosahexaenoic acid is an omega-3 fatty acid. DHA is metabolized to form the docosanoids, which comprise several families of potent hormones. DHA is a major fatty acid in sperm and brain phospholipids, particularly in the retina. Dietary DHA may reduce the risk of heart disease by reducing the level of blood triglycerides in humans. Low levels of DHA have been associated with Alzheimer's disease.
  • Folic acid also known as vitamin B9 or folacin
  • folate the naturally occurring form
  • pteroyl-L-glutamic acid and pteroyl-L-glutamate are forms of the water-soluble vitamin B9.
  • Folic acid is itself not biologically active, but its biological importance is due to tetrahydrofolate and other derivatives after its conversion to dihydrofolic acid in the liver.
  • Heart disease - Folic acid is a safe and effective supplement that targets large artery stiffness and may prevent isolated systolic hypertension, it may improve the integrity of the vascular endothelium.
  • Bone loss in Parkinson's disease (PD)-Folate lowers homocysteine (Hey) levels which in turn prevents bone loss in Parkinson's disease (PD) patients taking levodopa (a psychoactive drug taken to treat Parkinson's disease). Improvements in bone health include increased BMD at the lumbar spine, total femur, and femur shaft.
  • Schizophrenia-Folate deficiency may increase the risk of schizophrenia because by increasing homocysteine levels folate also increases interleukin 6 and tumor necrosis factor alpha levels and these two cytokines are involved in the development of schizophrenia.
  • Renal disease-Folic acid supplements may reduce the risk of children developing renal diseases or injuries such as microalbuminuria.
  • Lycopene It's a symmetrical tetraterpene assembled from 8 isoprene units. Their antioxidant property, substantial scientific and clinical research has been devoted to a possible correlation between lycopene consumption and general health. Early research suggested some amelioration of cardiovascular disease, cancer, diabetes, osteoporosis, and even male infertility. Lycopene helps neutralize harmful free radicals, which are implicated in cancer, heart disease, macular degeneration and other age-related illnesses. The evidence for a benefit was strongest for cancers of the prostate, lung, and stomach. Data were also suggestive of a benefit for cancers of the pancreas, colon and rectum, esophagus, oral cavity, breast, and cervix

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Cette invention concerne des antioxydants puissants, utiles pour tous les groupes d'âge. La composition basique est constituée des ingrédients suivants: EPA (150 mg), DHA (100 mg), acide folique (5 mg) et lycopène (50 mg). Le DHA est un acide gras principal présent dans le sperme, dans les phospholipides de cerveau, et en particulier dans la rétine. Le DHA diététique peut réduire le risque de maladie cardiaque par réduction du taux des triglycérides du sang chez les êtres humains. Le DHA a été associé, à de faibles niveaux, à la maladie d'Alzheimer. La vitamine B9 (acide folique et folate inclus) est essentielle pour de nombreuses fonctions organiques allant de la biosynthèse des nucléotides à la reméthylation de l'homocystéine. Le corps humain a besoin de folate pour synthétiser, réparer et méthyler l'ADN, ainsi que pour agir comme cofacteur dans des réactions biologiques faisant intervenir le folate. Il est particulièrement important en périodes de division cellulaire et de croissance rapide. Aussi bien les enfants que les adultes ont besoin d'acide folique pour produire des globules rouges sains et empêcher l'anémie. Le folate et l'acide folique tiennent leur nom du mot latin folium (qui signifie "feuille"). Les légumes-feuilles en sont une source principale, bien que dans les régimes alimentaires occidentaux, les céréales et le pain enrichis peuvent être une plus grande source alimentaire. L'EPA présente une action inhibitrice sur les enzymes hépatiques CYP2C9 et CYP2C19. À dose élevée, il peut également inhiber l'activité de CYP2D6 et CYP3A4, enzymes importantes intervenant dans le métabolisme d'un médicament. L'EPA améliore la réponse des patients à la chimiothérapie, éventuellement par modulation de la production des éicosanoïdes. Il pourrait également réduire le risque de développement de certains types de cancer, notamment le myélome multiple. Le lycopène contribue à neutraliser les radicaux libres nuisibles impliqués dans le cancer, la cardiopathie, la dégénérescence maculaire et autres maladies liées à l'âge. Les avantages ont été plus marqués s'agissant des cancers de la prostate, du poumon et de l'estomac. Des données ont été également suggéré concernant des avantages sur les cancers du pancréas, des côlon et rectum, de l'oesophage, de la cavité buccale, du sein, et du col de l'utérus.
PCT/IN2010/000872 2010-02-11 2010-12-30 Antioxydants actifs pour tous les groupes d'âge WO2011099031A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN373MU2010 2010-02-11
IN373/MUM/2010 2010-02-11

Publications (1)

Publication Number Publication Date
WO2011099031A1 true WO2011099031A1 (fr) 2011-08-18

Family

ID=44063945

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2010/000872 WO2011099031A1 (fr) 2010-02-11 2010-12-30 Antioxydants actifs pour tous les groupes d'âge

Country Status (1)

Country Link
WO (1) WO2011099031A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2759044C1 (ru) * 2020-09-23 2021-11-09 Федеральное государственное бюджетное учреждение "Российский научно-исследовательский институт гематологии и трансфузиологии Федерального медико-биологического агентства" (ФГБУ РосНИИГТ ФМБА России) Способ коррекции анемии в предоперационном периоде у больных раком желудка

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6649195B1 (en) 2002-07-11 2003-11-18 Vitacost.Com, Inc. Eyesight enhanced maintenance composition
WO2007076416A2 (fr) * 2005-12-20 2007-07-05 Alcon Research, Ltd. Composition et procedes d’inhibition de la progression d’une degeneration maculaire et promotion d’une vision saine
WO2009020595A2 (fr) * 2007-08-03 2009-02-12 Shaklee Corporation Système de complément nutritionnel
DE202009002126U1 (de) * 2009-02-13 2009-04-16 Orthomol Pharmazeutische Vertriebs Gmbh Spurenelement enthaltende Zusammensetzung
WO2009053824A1 (fr) 2007-10-23 2009-04-30 Laboratorio Chimico Internazionale S.P.A. Composition de pastilles d'acide lipoïque
GB2458466A (en) * 2008-03-18 2009-09-23 Kartar Singh Lalvani Composition for hair, skin and nail health maintenance

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6649195B1 (en) 2002-07-11 2003-11-18 Vitacost.Com, Inc. Eyesight enhanced maintenance composition
WO2007076416A2 (fr) * 2005-12-20 2007-07-05 Alcon Research, Ltd. Composition et procedes d’inhibition de la progression d’une degeneration maculaire et promotion d’une vision saine
WO2009020595A2 (fr) * 2007-08-03 2009-02-12 Shaklee Corporation Système de complément nutritionnel
WO2009053824A1 (fr) 2007-10-23 2009-04-30 Laboratorio Chimico Internazionale S.P.A. Composition de pastilles d'acide lipoïque
GB2458466A (en) * 2008-03-18 2009-09-23 Kartar Singh Lalvani Composition for hair, skin and nail health maintenance
DE202009002126U1 (de) * 2009-02-13 2009-04-16 Orthomol Pharmazeutische Vertriebs Gmbh Spurenelement enthaltende Zusammensetzung

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2759044C1 (ru) * 2020-09-23 2021-11-09 Федеральное государственное бюджетное учреждение "Российский научно-исследовательский институт гематологии и трансфузиологии Федерального медико-биологического агентства" (ФГБУ РосНИИГТ ФМБА России) Способ коррекции анемии в предоперационном периоде у больных раком желудка

Similar Documents

Publication Publication Date Title
KR20020025088A (ko) 필수지방산 및 호모시스테인-저하제를 포함하는 약제학적및 영양학적 조성물
DK2389077T3 (en) Nutritional supplements for individuals 50+ to improve vitality, immunity and health of the eyes and bones
JP2008501686A (ja) 栄養製剤
US20130101569A1 (en) Hair growth stimulant
US20020025310A1 (en) Compositions and methods for promoting healthy joints
JP7336994B2 (ja) 温熱療法治療を増強するための組成物および方法
US20240082197A1 (en) Delivery methods for omega-3's and compositions for vitamins and minerals used to enhance visual acuity and mental development in the human body
WO2008059965A1 (fr) Agent pour soulager ou prévenir des symptômes de stress et agent pour améliorer des états mentaux
Prasad Antioxidants in cancer care: when and how to use them as an adjunct to standard and experimental therapies
JP2015007092A (ja) 大量の栄養補給剤の負の副作用なしに、環境ストレスの作用に対抗し、免疫を改善し、活動力を改善し、一方でビタミンおよび無機質の欠乏に対処するための、マルチビタミン／無機質配合物
AT511776B1 (de) Verwendung von citrullin und ein kombinationspräparat zur verbesserung der männlichen fertilität
US20130064924A1 (en) Nutritional supplement for use under physiologically stressful conditions
US8557236B2 (en) Cardiovascular support supplement and compositions and methods thereof
EP2929879B1 (fr) Préparation combinée pour le traitement de l'infertilité associeé avec l'endometriose
WO2011099031A1 (fr) Antioxydants actifs pour tous les groupes d'âge
AT510810A1 (de) Kombinationspräparat zur verbesserung der weiblichen fertilität
WO2015069974A1 (fr) Capsules contenant des préparations de compléments alimentaires à absorption accrue de nutriments lipophiles
US11116246B2 (en) Compositions of coenzyme Q10 and methods of use
JP2021078397A (ja) 脂質減少促進剤
US20070031487A1 (en) Nutritional supplement for women
Van Schoor Vitamin and mineral supplements
JP2024517556A (ja) コエンザイムｑ１０含有液状補助飼料組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10824283

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10824283

Country of ref document: EP

Kind code of ref document: A1